Tag:

AstraZeneca

Latest Headlines

Latest Headlines

AstraZeneca rolls out preemie newspaper ads to fight Synagis limits

Drugmakers cheer when influential doctors' groups revise treatment guidelines to include new drugs. But as AstraZeneca's MedImmune unit knows, those groups can backpedal. 

AstraZeneca unit rolls out preemie newspaper ads to fight Synagis limits

Drugmakers cheer when doctors' groups revise treatment guidelines to include new drugs. What happens when these powerful professional associations change those recommendations unfavorably? If you're AstraZeneca's MedImmune business, you fight back with sensational newspaper advertising.

AstraZeneca reaches out to Roche with a would-be cancer blockbuster

AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $3 billion a year at its peak, and the drugmaker is working with rival Roche to craft a blood test that can spot ideal patients for the therapy.

AstraZeneca inks deal with Advaxis for immunotherapy-vaccine combo trial

AstraZeneca's MedImmune has joined up with immunotherapy maker Advaxis to evaluate the Big Pharma's antibody MEDI4736 in conjunction with the Princeton, NJ-based biotech's lead cancer vaccine in patients with HPV-related cancers.

AstraZeneca adds Advaxis to a growing roster of immuno-oncology partners

AstraZeneca has partnered up with Princeton, NJ-based Advaxis on a program that pairs the pharma giant's closely-watched immuno-oncology drug MEDI4736 with the biotech's therapeutic cancer vaccine for HPV-related cancers.

AstraZeneca dishes on its $500M new home in Cambridge, U.K.

AstraZeneca's sweeping new Cambridge, U.K., campus will be constructed with collaboration in mind, the company said, unveiling plans for the $500 million site it aims to open in 2016.

AstraZeneca spreads its virtual reach to cardio R&D with new partnership

AstraZeneca is expanding iMed, its virtual R&D project, through a cardiovascular-focused agreement with Germany's Max Planck Institute of Molecular Physiology that will focus on early-stage research.

AstraZeneca, MRC Technology renew preclinical pact

The pact focuses on identifying and selecting novel drug targets with the potential to become potent, selective therapeutics in the areas of oncology, inflammation and diabetes.

U.K. fund manager Neil Woodford bets big on AstraZeneca

Plenty of AstraZeneca fans voiced their support for a standalone company when Pfizer tried to take the drugmaker over earlier this year. But actions speak louder than words, and now one vocal advocate is putting his money where his mouth is.

Apparently confident AstraZeneca CEO socks $3.4M into company shares

Pascal Soriot has raised the stakes on AstraZeneca's turnaround. The chief executive plunked down $3.4 million to buy more of his company's shares.